diff --git a/pages/STOP2030___Annual Meeting___2024___Notas.md b/pages/STOP2030___Annual Meeting___2024___Notas.md
index 6fffbb14..7ce4f445 100644
--- a/pages/STOP2030___Annual Meeting___2024___Notas.md	
+++ b/pages/STOP2030___Annual Meeting___2024___Notas.md	
@@ -13,4 +13,4 @@
 - [[Doris Njomo]]: ESACIPAC has been conducting research about the program for STH. Mantain an evidence based approach. There has been a significar reduction at baseline STH. we're approaching the <2%. However this reduction is only to los 3. Due to the resistance of Strongy and Trichuris. They don't respond effectively to alb. It can be a gamechanger and a promising intervention for the WHO goals. We still have a lot of work to do. But treatment of SAC is the entry point. Also represent the director general of KEMRI. I'm going to read. The results of this project are equally being awaited. not only in kenya but many countries burdened. specially for SAC. KEMRI support.
 - [[Julie Jacobson]] and [[Alan Brooks]]: We need to make sure that we can anticipate and answer the questions to make this a public health intervention. Encourage everyone to think outside your area of work. Flipboard. Go anytime you want to. Idea to contribute, question to ask. Connections to drive to success. What a rewarding opening session. We're working towards healthier childern, women and their babies. How do we get there? Its born on science, on strong and rigorous sciece and now how do we make it available. What is the importance of the FDC. Its an answer to a call. The current drugs didn't have the full coverage. Clinics and MDA distribuuytion. It keeps distribution simple. If we make this complicated it wont be easily accepted. The largest risk of MDA is chocking. Its orodispersible. mango flavoured. Integration. 2 drugs that treat multiple NTDs. anticipate risk of resistance. What evidence is needed for WHO and countries to say: yes, we're introducing it. One regimen for children and one for adults. What's the policy pathway through WHO. There has already been a Phase II/III, REALISE trial for safety. The target is a prequalified product. Shelf life is around 2 years, doesn't need any special conditions. Who is going to make it? Will the supply be available? THey have the capacity to do this. They're producing many drugs at scale around the world. This wont be a donated product. We're not on the position to create another donated product. keep it as affordable as possible and funding oportunities. Where do we come: the fdc is a new product and an old approach. alb/ivm have been used frequently for LF. In our conversations with WHO about how to better give them the info is a WHO Policy Brief and it looks like the best pathway. rigorous
 - [[Ale]]: Will the Policy Brief include the recomendation of the FDC? Its something to be discussed. What [[Julie]] just showed is that WP2 is leading the biomedical studies. WP4: acceptaibiliuy and social studies. WP3 put everything together, modelling to incoporate the evidence gathered. incorporate to WP5 and make the final moves.
--
\ No newline at end of file
+- QUestion: within the work packages. programs will need to buy this commodity. We need to have some cost evaluation or benefits.
\ No newline at end of file